Lorraine Pamela D'Alessio - 09 Sep 2025 Form 4 Insider Report for MANGOCEUTICALS, INC. (MGRX)

Reporting relationship: Director
Issuer ticker: MGRX
Reported as of: 09 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Sep 2025, 16:57:49 UTC
Prior SEC filing: 11 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ Lorraine D'Alessio

Key filing fact

Lorraine Pamela D'Alessio filed Form 4 for MANGOCEUTICALS, INC. (MGRX) on 12 Sep 2025.

Key facts

This page summarizes Lorraine Pamela D'Alessio's Form 4 filing for MANGOCEUTICALS, INC. (MGRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 12 Sep 2025, 16:57.

Change

Previous filing in this sequence was filed on 11 Apr 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001905593 Primary reporting owner

D'Alessio Lorraine Pamela

Relationship: Director
Address: C/O MANGOCEUTICALS, INC., 15110 N. DALLAS PARKWAY, SUITE 600, DALLAS
Signature: /s/ Lorraine D'Alessio
Signature date: 11 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MGRX transaction

Common Stock

Award

Transaction value: $0
Shares: +100,000
Change %: +273%
Price: $0.000000
Shares after: 136,667
Date: 09 Sep 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Issued as a discretionary bonus in consideration for services rendered as a member of the Board of Directors. Issued under the registrant's Second Amended and Restated 2022 Equity Incentive Plan. Exempt pursuant to Rule 16b-3.